17 results on '"Pedreño-Lopez, Núria"'
Search Results
2. Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models
- Author
-
Usai, Carla, Ainsua-Enrich, Erola, Gales, Victor Urrea, Pradenas, Edwards, Lorca-Oró, Cristina, Tarrés-Freixas, Ferran, Roca, Núria, Pérez, Mónica, Ávila-Nieto, Carlos, Rodríguez de la Concepción, María Luisa, Pedreño-Lopez, Núria, Carabelli, Julieta, Trinité, Benjamin, Ballana, Ester, Riveira-Muñoz, Eva, Izquierdo-Useros, Nuria, Clotet, Bonaventura, Blanco, Julià, Guallar, Victor, Cantero, Guillermo, Vergara-Alert, Júlia, Carrillo, Jorge, and Segalés, Joaquim
- Published
- 2024
- Full Text
- View/download PDF
3. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
- Author
-
Ainsua-Enrich, Erola, Pedreño-Lopez, Núria, Bracke, Carmen, Ávila-Nieto, Carlos, Rodríguez de la Concepción, María Luisa, Pradenas, Edwards, Trinité, Benjamin, Marfil, Silvia, Miranda, Cristina, González, Sandra, Toledo, Ruth, Font, Marta, Benet, Susana, Escribà, Tuixent, Jimenez-Moyano, Esther, Peña, Ruth, Cedeño, Samandhy, Prado, Julia G., Mothe, Beatriz, Brander, Christian, Izquierdo-Useros, Nuria, Vergara-Alert, Julia, Segalés, Joaquim, Massanella, Marta, Benitez, Rosa María, Romero, Alba, Molina-Morant, Daniel, Blanco, Julià, Clotet, Bonaventura, Mateu, Lourdes, Pedro-Botet, María Luisa, and Carrillo, Jorge
- Published
- 2022
- Full Text
- View/download PDF
4. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine
- Author
-
Wec, Anna Z., Haslwanter, Denise, Abdiche, Yasmina N., Shehata, Laila, Pedreño-Lopez, Nuria, Moyer, Crystal L., Bornholdt, Zachary A., Lilov, Asparouh, Nett, Juergen H., Jangra, Rohit K., Brown, Michael, Watkins, David I., Ahlm, Clas, Forsell, Mattias N., Rey, Félix A., Barba-Spaeth, Giovanna, Chandran, Kartik, and Walker, Laura M.
- Published
- 2020
5. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
- Author
-
Ávila-Nieto, Carlos, Vergara-Alert, Júlia, Amengual-Rigo, Pep, Ainsua-Enrich, Erola, Brustolin, Marco, Rodríguez de la Concepción, María Luisa, Pedreño-Lopez, Núria, Rodon, Jordi, Urrea, Victor, Pradenas, Edwards, Marfil, Silvia, Ballana, Ester, Riveira-Muñoz, Eva, Pérez, Mònica, Roca, Núria, Tarrés-Freixas, Ferran, Carabelli, Julieta, Cantero, Guillermo, Pons-Grífols, Anna, and Rovirosa, Carla
- Subjects
GOLDEN hamster ,SARS-CoV-2 ,SARS-CoV-2 Delta variant ,COVID-19 vaccines ,MICE - Abstract
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques
- Author
-
Magnani, Diogo M., Rogers, Thomas F., Beutler, Nathan, Ricciardi, Michael J., Bailey, Varian K., Gonzalez-Nieto, Lucas, Briney, Bryan, Sok, Devin, Le, Khoa, Strubel, Alexander, Gutman, Martin J., Pedreño-Lopez, Núria, Grubaugh, Nathan D., Silveira, Cassia G. T., Maxwell, Helen S., Domingues, Aline, Martins, Mauricio A., Lee, David E., Okwuazi, Erica E., Jean, Sherrie, Strobert, Elizabeth A., Chahroudi, Ann, Silvestri, Guido, Vanderford, Thomas H., Kallas, Esper G., Desrosiers, Ronald C., Bonaldo, Myrna C., Whitehead, Stephen S., Burton, Dennis R., and Watkins, David I.
- Published
- 2017
- Full Text
- View/download PDF
7. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
- Author
-
Benet, Susana, Blanch-Lombarte, Oscar, Ainsua-Enrich, Erola, Pedreño-Lopez, Núria, Muñoz-Basagoiti, Jordana, Raïch-Regué, Dàlia, Perez-Zsolt, Daniel, Peña, Ruth, Jiménez, Esther, Concepción, María Luisa Rodríguez de la, Ávila, Carlos, Cedeño, Samandhy, Escribà, Tuixent, Romero-Martín, Luis, Alarcón-Soto, Yovaninna, Rodriguez-Lozano, Gabriel Felipe, Miranda, Cristina, González, Sandra, Bailón, Lucía, and Blanco, Julià
- Subjects
SARS-CoV-2 ,COVID-19 ,T cells - Abstract
Background: We analyzed humoral and cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in people with human immunodeficiency virus (HIV; PWH) who had CD4+ T-cell counts <200/µL (HIV<200 group).Methods: This prospective cohort study included 58 PWH in the HIV<200 group, 36 with CD4+ T-cell counts >500/µL (HIV>500 group), and 33 HIV-1-negative controls (control group). Antibodies against the SARS-CoV-2 spike protein (anti-S immunoglobulin [Ig] G) and the receptor-binding domain (anti-RBD IgG) were quantified before and 4 weeks after the first and the second doses of BNT162b2 or mRNA-1273 (at week 8). Viral neutralization activity and T-cell responses were also determined.Results: At week 8, anti-S/anti-RBD IgG responses increased in all groups (P < .001). Median (interquartile range) anti-S and anti-RBD IgG levels at week 8 were 153.6 (26.4-654.9) and 171.9 (61.8-425.8) binding antibody units (BAU)/mL, respectively, in the HIV<200 group, compared with 245.6 (145-824) and 555.8 (166.4-1751) BAU/mL in the HIV>500 group and 274.7 (193.7-680.4) and 281.6 (181-831.8) BAU/mL in controls (P < .05). Neutralizing capacity and specific T-cell immune responses were absent or reduced in 33% of those in the HIV<200 group, compared with 3.7% in the HIV>500 group (P < .01).Conclusions: One-third of PWH with CD4+ T-cell counts <200/µL show low anti-S/anti-RBD IgG levels, reduced in vitro neutralization activity against SARS-CoV-2, and no vaccine-induced T cells after receiving coronavirus disease 2019 mRNA vaccines. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques.
- Author
-
Magnani, Diogo M., Rogers, Thomas F., Maness, Nicholas J., Grubaugh, Nathan D., Beutler, Nathan, Bailey, Varian K., Gonzalez-Nieto, Lucas, Gutman, Martin J., Pedreño-Lopez, Núria, Kwal, Jaclyn M., Ricciardi, Michael J., Myers, Tereance A., Julander, Justin G., Bohm, Rudolf P., Gilbert, Margaret H., Schiro, Faith, Aye, Pyone P., Blair, Robert V., Martins, Mauricio A., and Falkenstein, Kathrine P.
- Abstract
Zika virus (ZIKV) infection of pregnant women is associated with pathologic complications of fetal development. Here, we infect pregnant rhesus macaques (Macaca mulatta) with a minimally passaged ZIKV isolate from Rio de Janeiro, where a high rate of fetal development complications was observed. The infection of pregnant macaques with this virus results in maternal viremia, virus crossing into the amniotic fluid (AF), and in utero fetal deaths. We also treated three additional ZIKV-infected pregnant macaques with a cocktail of ZIKVneutralizing human monoclonal antibodies (nmAbs) at peak viremia. While the nmAbs can be effective in clearing the virus from the maternal sera of treated monkeys, it is not sufficient to clear ZIKV from AF. Our report suggests that ZIKV from Brazil causes fetal demise in nonhuman primates (NHPs) without additional mutations or confounding co-factors. Treatment with a neutralizing anti-ZIKV nmAb cocktail is insufficient to fully stop vertical transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL.
- Author
-
Ricciardi, Michael J., Magnani, Diogo M., Grifoni, Alba, Kwon, Young-Chan, Gutman, Martin J., Grubaugh, Nathan D., Gangavarapu, Karthik, Sharkey, Mark, Silveira, Cassia G. T., Bailey, Varian K., Pedreño-Lopez, Núria, Gonzalez-Nieto, Lucas, Maxwell, Helen S., Domingues, Aline, Martins, Mauricio A., Pham, John, Weiskopf, Daniela, Altman, John, Kallas, Esper G., and Andersen, Kristian G.
- Subjects
B cells ,T cells ,ZIKA virus infections ,DENGUE ,IMMUNE response ,IMMUNOGLOBULIN G ,IMMUNOGLOBULIN M ,PATIENTS ,PREVENTION - Abstract
Zika virus (ZIKV) is a mosquito-borne flavivirus of significant public health concern. In the summer of 2016, ZIKV was first detected in the contiguous United States. Here we present one of the first cases of a locally acquired ZIKV infection in a dengue-naïve individual. We collected blood from a female with a maculopapular rash at day (D) 5 and D7 post onset of symptoms (POS) and we continued weekly blood draws out to D148 POS. To establish the ontogeny of the immune response against ZIKV, lymphocytes and plasma were analyzed in a longitudinal fashion. The plasmablast response peaked at D7 POS (19.6% of CD19
+ B-cells) and was undetectable by D15 POS. ZIKV-specific IgM was present at D5 POS, peaked between D15 and D21 POS, and subsequently decreased. The ZIKV-specific IgG response, however, was not detected until D15 POS and continued to increase after that. Interestingly, even though the patient had never been infected with dengue virus (DENV), cross-reactive IgM and IgG binding against each of the four DENV serotypes could be detected. The highest plasma neutralization activity against ZIKV peaked between D15 and D21 POS, and even though DENV binding antibodies were present in the plasma of the patient, there was neither neutralization nor antibody dependent enhancement (ADE) of DENV. Interestingly, ADE against ZIKV arose at D48 POS and continued until the end of the study. CD4+ and CD8+ T-cells recognized ZIKV-NS2A and ZIKV-E, respectively. The tetramer positive CD8+ T-cell response peaked at D21 POS with elevated levels persisting for months. In summary, this is the first study to establish the timing of the ontogeny of the immune response against ZIKV. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.
- Author
-
Magnani, Diogo M., Silveira, Cassia G. T., Rosen, Brandon C., Ricciardi, Michael J., Pedreño-Lopez, Núria, Gutman, Martin J., Bailey, Varian K., Maxwell, Helen S., Domingues, Aline, Gonzalez-Nieto, Lucas, Avelino-Silva, Vivian I., Trindade, Mateus, Nogueira, Juliana, Oliveira, Consuelo S., Maestri, Alvino, Felix, Alvina Clara, Levi, José Eduardo, Nogueira, Mauricio L., Martins, Mauricio A., and Martinez-Navio, José M.
- Subjects
ZIKA virus infections ,IMMUNOGLOBULINS ,GERM cells ,EPITOPES ,SOMATIC mutation ,IMMUNOREGULATION ,THERAPEUTICS - Abstract
The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut
50 ~ 2 μg/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.
- Author
-
Haslwanter, Denise, Lasso, Gorka, Wec, Anna Z., Furtado, Nathália Dias, Raphael, Lidiane Menezes Souza, Tse, Alexandra L., Sun, Yan, Stransky, Stephanie, Pedreño-Lopez, Núria, Correia, Carolina Argondizo, Bornholdt, Zachary A., Sakharkar, Mrunal, Avelino-Silva, Vivian I., Moyer, Crystal L., Watkins, David I., Kallas, Esper G., Sidoli, Simone, Walker, Laura M., Bonaldo, Myrna C., and Chandran, Kartik
- Abstract
The resurgence of yellow fever in South America has prompted vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a live-attenuated YF-17D virus derived from a virulent African isolate. The capacity of these vaccines to induce neutralizing antibodies against the vaccine strain is used as a surrogate for protection. However, the sensitivity of genetically distinct South American strains to vaccine-induced antibodies is unknown. We show that antiviral potency of the polyclonal antibody response in vaccinees is attenuated against an emergent Brazilian strain. This reduction was attributable to amino acid changes at two sites in central domain II of the glycoprotein E, including multiple changes at the domain I–domain II hinge, which are unique to and shared among most South American YFV strains. Our findings call for a reevaluation of current approaches to YFV immunological surveillance in South America and suggest approaches for updating vaccines. [Display omitted] • YFV vaccine-induced neutralization is attenuated against South American YFV strains • Reduced neutralization sensitivity genetically maps to domain II of the E protein • Multiple genetic changes in domain I–domain II hinge affect antibody recognition • Approach to YFV immunological surveillance in South America should be reevaluated Yellow fever vaccines based on an African strain induce neutralizing antibodies that are associated with protection. Haslwanter et al. show that these antibodies have reduced activity against South American strains because hey bear genetically distinct surface proteins, suggesting that changes are needed in how immune protection against YFV is monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.
- Author
-
Martins, Mauricio A., Tully, Damien C., Pedreño-Lopez, Núria, Von Bredow, Benjamin, Pauthner, Matthias G., Shin, Young C., Yuan, Maoli, Lima, Noemia S., Bean, David J., Gonzalez-Nieto, Lucas, Domingues, Aline, Gutman, Martin J., Maxwell, Helen S., Magnani, Diogo M., Ricciardi, Michael J., Bailey, Varian K., Altman, John D., Burton, Dennis R., Ejima, Keisuke, and Allison, David B.
- Subjects
- *
RHESUS monkeys , *MAJOR histocompatibility complex , *ANIMAL vaccination , *SIMIAN immunodeficiency virus diseases , *HIV prevention - Abstract
Certain major histocompatibility complex class I (MHC-I) alleles are associated with spontaneous control of viral replication in human immunodeficiency virus (HIV)-infected people and simian immunodeficiency virus (SIV)- infected rhesus macaques (RMs). These cases of "elite" control of HIV/SIV replication are often immune-mediated, thereby providing a framework for studying anti-lentiviral immunity. In this study, we examined how vaccination impacts SIV replication in RMs expressing the MHC-I allele Mamu-B*17. Approximately 21% of Mamu-B*17+ and 50% of Mamu-B*08+ RMs control chronic-phase viremia after SIVmac239 infection. Because CD8+ T cells targeting Mamu-B*08-restricted SIV epitopes have been implicated in virologic suppression in Mamu-B*08+ RMs, we investigated whether this might also be true for Mamu-B*17+ RMs. Two groups of Mamu-B*17+ RMs were vaccinated with genes encoding Mamu-B*17-restricted epitopes in Vif and Nef. These genes were delivered by themselves (group 1) or together with env (group 2). Group 3 included MHC-I-matched RMs and served as the control group. Surprisingly, the group 1 vaccine regimen had little effect on viral replication compared to group 3, suggesting that unlike Mamu-B*08+ RMs, preexisting SIV-specific CD8+ T cells alone do not facilitate long-term virologic suppression in Mamu-B*17+ RMs. Remarkably, however, 5/8 group 2 vaccinees controlled viremia to <15 viral RNA copies/ml soon after infection. No serological neutralizing activity against SIVmac239 was detected in group 2, although vaccine-elicited gp140-binding antibodies correlated inversely with nadir viral loads. Collectively, these data shed new light on the unique mechanism of elite control in Mamu-B*17+ RMs and implicate vaccine-induced, nonneutralizing anti- Env antibodies in the containment of immunodeficiency virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08+ Rhesus Macaques.
- Author
-
Martins, Mauricio A., Gonzalez-Nieto, Lucas, Shin, Young C., Domingues, Aline, Gutman, Martin J., Maxwell, Helen S., Magnani, Diogo M., Ricciardi, Michael J., Pedreño-Lopez, Núria, Bailey, Varian K., Altman, John D., Parks, Christopher L., Allison, David B., Ejima, Keisuke, Rakasz, Eva G., Capuano III, Saverio, Desrosiers, Ronald C., Lifson, Jeffrey D., and Watkins, David I.
- Subjects
- *
RHESUS monkeys , *SIMIAN immunodeficiency virus diseases vaccines , *T cells , *CD8 antigen , *HIV infections - Abstract
Approximately 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (MHC-I) allele Mamu-B*08 spontaneously control chronic-phase viremia after infection with the pathogenic simian immunodeficiency virus mac239 (SIVmac239) clone. CD8+ T-cell responses in these animals are focused on immunodominant Mamu-B*08-restricted SIV epitopes in Vif and Nef, and prophylactic vaccination with these epitopes increases the incidence of elite control in SIVmac239-infected Mamu-B*08-positive (Mamu-B*08+) RMs. Here we evaluated if robust vaccine-elicited CD8+ T-cell responses against Vif and Nef can prevent systemic infection in Mamu-B*08+ RMs following mucosal SIV challenges. Ten Mamu-B*08+ RMs were vaccinated with a heterologous prime/boost/boost regimen encoding Vif and Nef, while six sham-vaccinated MHC-I-matched RMs served as the controls for this experiment. Vaccine-induced CD8+ T cells against Mamu-B*08-restricted SIV epitopes reached high frequencies in blood but were present at lower levels in lymph node and gut biopsy specimens. Following repeated intrarectal challenges with SIVmac239, all control RMs became infected by the sixth SIV exposure. By comparison, four vaccinees were still uninfected after six challenges, and three of them remained aviremic after 3 or 4 additional challenges. The rate of SIV acquisition in the vaccinees was numerically lower (albeit not statistically significantly) than that in the controls. However, peak viremia was significantly reduced in infected vaccinees compared to control animals. We found no T-cell markers that distinguished vaccinees that acquired SIV infection from those that did not. Additional studies will be needed to validate these findings and determine if cellular immunity can be harnessed to prevent the establishment of productive immunodeficiency virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
- Author
-
Magnani, Diogo M., Silveira, Cassia G. T., Ricciardi, Michael J., Gonzalez-Nieto, Lucas, Pedreño-Lopez, Núria, Bailey, Varian K., Gutman, Martin J., Maxwell, Helen S., Domingues, Aline, Costa, Priscilla R., Ferrari, Lilian, Goulart, Raphaella, Martins, Mauricio A., Martinez-Navio, José M., Fuchs, Sebastian P., Kalil, Jorge, do Carmo Timenetsky, Maria, Wrammert, Jens, Whitehead, Stephen S., and Burton, Dennis R.
- Subjects
- *
DENGUE viruses , *DENGUE , *B cells , *MONOCLONAL antibodies , *NATURAL immunity , *VACCINATION - Abstract
Exposure to dengue virus (DENV) is thought to elicit lifelong immunity, mediated by DENV-neutralizing antibodies (nAbs). However, Abs generated by primary infections confer serotype-specific protection, and immunity against other serotypes develops only after subsequent infections. Accordingly, the induction of these nAb responses acquired after serial DENV infections has been a long-soughtafter goal for vaccination. Nonetheless, it is still unclear if tetravalent vaccines can elicit or recall nAbs. In this study, we have characterized the responses from a volunteer who had been previously exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, developed by the NIH and Butantan Institute. Eleven days after vaccination, we observed an ~70-fold expansion of the plasmablast population. We generated 21 monoclonal Abs (MAbs) from singly sorted plasmablasts. These MAbs were the result of clonal expansions and had significant levels of somatic hypermutation (SHM). Nineteen MAbs (90.5%) neutralized at least one DENV serotype at concentrations of 1 μg/ml or less; 6 of the 21 MAbs neutralized three or more serotypes. Despite the tetravalent composition of the vaccine, we observed a neutralization bias in the induced repertoire: DENV3 was targeted by 18 of the 19 neutralizing MAbs (nMAbs). Furthermore, the P3D05 nMAb neutralized DENV3 with extraordinary potency (concentration to achieve half-maximal neutralization [Neut50] = 0.03 μg/ml). Thus, the Butantan-DV vaccine engendered a mature, antigen-selected B cell repertoire. Our results suggest that preexisting responses elicited by a previous DENV3 infection were recalled by immunization. IMPORTANCE The dengue epidemic presents a global public health challenge that causes widespread economic burden and remains largely unchecked by existing control strategies. Successful control of the dengue epidemic will require effective prophylactic and therapeutic interventions. Several vaccine clinical efficacy trials are approaching completion, and the chances that one or more live attenuated tetravalent vaccines (LATVs) will be introduced worldwide is higher than ever. While it is widely accepted that dengue virus (DENV)-neutralizing antibody (nAb) titers are associated with protection, the Ab repertoire induced by LATVs remain uncharacterized. Here, we describe the isolation of potent (Neut50 < 0.1 μg/ml) nAbs from a DENV-seropositive volunteer immunized with the tetravalent vaccine Butantan-DV, which is currently in phase III trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08 + Rhesus Macaques.
- Author
-
Martins MA, Gonzalez-Nieto L, Shin YC, Domingues A, Gutman MJ, Maxwell HS, Magnani DM, Ricciardi MJ, Pedreño-Lopez N, Bailey VK, Altman JD, Parks CL, Allison DB, Ejima K, Rakasz EG, Capuano S 3rd, Desrosiers RC, Lifson JD, and Watkins DI
- Subjects
- Animals, Epitopes, T-Lymphocyte immunology, Gene Products, nef administration & dosage, Gene Products, vif administration & dosage, Histocompatibility Antigens Class I immunology, Macaca mulatta, Vaccination, Viral Vaccines immunology, Viremia immunology, CD8-Positive T-Lymphocytes immunology, Gene Products, nef immunology, Gene Products, vif immunology, SAIDS Vaccines immunology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Immunodeficiency Virus immunology
- Abstract
Approximately 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (MHC-I) allele Mamu-B*08 spontaneously control chronic-phase viremia after infection with the pathogenic simian immunodeficiency virus mac239 (SIVmac239) clone. CD8
+ T-cell responses in these animals are focused on immunodominant Mamu-B*08-restricted SIV epitopes in Vif and Nef, and prophylactic vaccination with these epitopes increases the incidence of elite control in SIVmac239-infected Mamu-B*08 -positive ( Mamu-B*08+ ) RMs. Here we evaluated if robust vaccine-elicited CD8+ T-cell responses against Vif and Nef can prevent systemic infection in Mamu-B*08+ RMs following mucosal SIV challenges. Ten Mamu-B*08+ RMs were vaccinated with a heterologous prime/boost/boost regimen encoding Vif and Nef, while six sham-vaccinated MHC-I-matched RMs served as the controls for this experiment. Vaccine-induced CD8+ T cells against Mamu-B*08-restricted SIV epitopes reached high frequencies in blood but were present at lower levels in lymph node and gut biopsy specimens. Following repeated intrarectal challenges with SIVmac239, all control RMs became infected by the sixth SIV exposure. By comparison, four vaccinees were still uninfected after six challenges, and three of them remained aviremic after 3 or 4 additional challenges. The rate of SIV acquisition in the vaccinees was numerically lower (albeit not statistically significantly) than that in the controls. However, peak viremia was significantly reduced in infected vaccinees compared to control animals. We found no T-cell markers that distinguished vaccinees that acquired SIV infection from those that did not. Additional studies will be needed to validate these findings and determine if cellular immunity can be harnessed to prevent the establishment of productive immunodeficiency virus infection. IMPORTANCE It is generally accepted that the antiviral effects of vaccine-induced classical CD8+ T-cell responses against human immunodeficiency virus (HIV) are limited to partial reductions in viremia after the establishment of productive infection. Here we show that rhesus macaques (RMs) vaccinated with Vif and Nef acquired simian immunodeficiency virus (SIV) infection at a lower (albeit not statistically significant) rate than control RMs following repeated intrarectal challenges with a pathogenic SIV clone. All animals in the present experiment expressed the elite control-associated major histocompatibility complex class I (MHC-I) molecule Mamu-B*08 that binds immunodominant epitopes in Vif and Nef. Though preliminary, these results provide tantalizing evidence that the protective efficacy of vaccine-elicited CD8+ T cells may be greater than previously thought. Future studies should examine if vaccine-induced cellular immunity can prevent systemic viral replication in RMs that do not express MHC-I alleles associated with elite control of SIV infection., (Copyright © 2019 American Society for Microbiology.)- Published
- 2019
- Full Text
- View/download PDF
16. Mamu-B*17 + Rhesus Macaques Vaccinated with env , vif , and nef Manifest Early Control of SIVmac239 Replication.
- Author
-
Martins MA, Tully DC, Pedreño-Lopez N, von Bredow B, Pauthner MG, Shin YC, Yuan M, Lima NS, Bean DJ, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Magnani DM, Ricciardi MJ, Bailey VK, Altman JD, Burton DR, Ejima K, Allison DB, Evans DT, Rakasz EG, Parks CL, Bonaldo MC, Capuano S 3rd, Lifson JD, Desrosiers RC, Allen TM, and Watkins DI
- Subjects
- Alleles, Animals, Antibodies, Neutralizing blood, Antibodies, Viral blood, Macaca mulatta, SAIDS Vaccines administration & dosage, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus physiology, Viral Load, Viremia prevention & control, Virus Replication, Gene Products, env immunology, Gene Products, nef immunology, Gene Products, vif immunology, Histocompatibility Antigens Class I genetics, SAIDS Vaccines immunology, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus immunology
- Abstract
Certain major histocompatibility complex class I (MHC-I) alleles are associated with spontaneous control of viral replication in human immunodeficiency virus (HIV)-infected people and simian immunodeficiency virus (SIV)-infected rhesus macaques (RMs). These cases of "elite" control of HIV/SIV replication are often immune-mediated, thereby providing a framework for studying anti-lentiviral immunity. In this study, we examined how vaccination impacts SIV replication in RMs expressing the MHC-I allele Mamu-B*17 Approximately 21% of Mamu-B*17
+ and 50% of Mamu-B*08+ RMs control chronic-phase viremia after SIVmac239 infection. Because CD8+ T cells targeting Mamu-B*08-restricted SIV epitopes have been implicated in virologic suppression in Mamu-B*08+ RMs, we investigated whether this might also be true for Mamu-B*17+ RMs. Two groups of Mamu-B*17+ RMs were vaccinated with genes encoding Mamu-B*17-restricted epitopes in Vif and Nef. These genes were delivered by themselves (group 1) or together with env (group 2). Group 3 included MHC-I-matched RMs and served as the control group. Surprisingly, the group 1 vaccine regimen had little effect on viral replication compared to group 3, suggesting that unlike Mamu-B*08+ RMs, preexisting SIV-specific CD8+ T cells alone do not facilitate long-term virologic suppression in Mamu-B*17+ RMs. Remarkably, however, 5/8 group 2 vaccinees controlled viremia to <15 viral RNA copies/ml soon after infection. No serological neutralizing activity against SIVmac239 was detected in group 2, although vaccine-elicited gp140-binding antibodies correlated inversely with nadir viral loads. Collectively, these data shed new light on the unique mechanism of elite control in Mamu-B*17+ RMs and implicate vaccine-induced, nonneutralizing anti-Env antibodies in the containment of immunodeficiency virus infection. IMPORTANCE A better understanding of the immune correlates of protection against HIV might facilitate the development of a prophylactic vaccine. Therefore, we investigated simian immunodeficiency virus (SIV) infection outcomes in rhesus macaques expressing the major histocompatibility complex class I allele Mamu-B*17 Approximately 21% of Mamu-B*17+ macaques spontaneously controlled chronic phase viremia after SIV infection, an effect that may involve CD8+ T cells targeting Mamu-B*17-restricted SIV epitopes. We vaccinated Mamu-B*17+ macaques with genes encoding immunodominant epitopes in Vif and Nef alone (group 1) or together with env (group 2). Although neither vaccine regimen prevented SIV infection, 5/8 group 2 vaccinees controlled viremia to below detection limits shortly after infection. This outcome, which was not observed in group 1, was associated with vaccine-induced, nonneutralizing Env-binding antibodies. Together, these findings suggest a limited contribution of Vif- and Nef-specific CD8+ T cells for virologic control in Mamu-B*17+ macaques and implicate anti-Env antibodies in containment of SIV infection., (Copyright © 2018 American Society for Microbiology.)- Published
- 2018
- Full Text
- View/download PDF
17. Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.
- Author
-
Magnani DM, Ricciardi MJ, Bailey VK, Gutman MJ, Pedreño-Lopez N, Silveira CGT, Maxwell HS, Domingues A, Gonzalez-Nieto L, Su Q, Newman RM, Pack M, Martins MA, Martinez-Navio JM, Fuchs SP, Rakasz EG, Allen TM, Whitehead SS, Burton DR, Gao G, Desrosiers RC, Kallas EG, and Watkins DI
- Subjects
- Animals, Enzyme-Linked Immunosorbent Assay, Female, Macaca mulatta, Male, Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Dengue Virus immunology, Dependovirus genetics
- Abstract
Development of vaccines against mosquito-borne Flaviviruses is complicated by the occurrence of antibody-dependent enhancement (ADE), which can increase disease severity. Long-term delivery of neutralizing antibodies (nAbs) has the potential to effectively block infection and represents an alternative to vaccination. The risk of ADE may be avoided by using prophylactic nAbs harboring amino acid mutations L234A and L235A (LALA) in the immunoglobulin G (IgG) constant region. Here, we used recombinant adeno-associated viruses (rAAVs) to deliver the anti-dengue virus 3 (DENV3) nAb P3D05. While the administration of rAAV-P3D05-rhesus immunoglobulin G1 (rhIgG1)-LALA to rhesus macaques engendered DENV3-neutralizing activity in serum, it did not prevent infection. The emergence of viremia following DENV3 challenge was delayed by 3-6 days in the rAAV-treated group, and replicating virus contained the envelope mutation K64R. This neutralization-resistant variant was also confirmed by virus outgrowth experiments in vitro. By delivering P3D05 with unmutated Fc sequences, we further demonstrated that DENV3 also evaded wild-type nAb prophylaxis, and serum viral loads appeared to be higher in the presence of low levels of unmutated P3D05-rhIgG1. Our study shows that a vectored approach for long-term delivery of nAbs with the LALA mutations is promising, but prophylaxis using a single nAb is likely insufficient at preventing DENV infection and replication., (Copyright © 2017 The American Society of Gene and Cell Therapy. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.